Fertility and Pregnancy-Related Issues in Young BRCA Carriers With Breast Cancer.
Isotta Martha MagatonLuca AreccoElene MariamidzeKristina JankovicMihaela StanaGiulia BuzzattiLucia TrevisanGraziana ScavoneSilvia OttonelloPiero FregattiClaudia MassarottiMichael von WolffMatteo LambertiniPublished in: Breast cancer : basic and clinical research (2024)
Approximately 10% to 15% of breast cancer cases in young women are diagnosed in patients harbouring germline (g) pathogenic or likely pathogenic variants (PVs) in the BReast CAncer 1 ( BRCA1 ) or BReast CAncer 2 ( BRCA2 ) genes. Preclinical and clinical studies showed a potential negative effect of germline BRCA 1/2 (g BRCA1/2 ) PVs on ovarian reserve and reproductive potential, even before starting anticancer therapies. The aim of this article is to summarize the current literature on the fertility potential of young g BRCA1/2 PVs carriers with breast cancer and the risk of gonadotoxicity associated with anticancer treatments. Moreover, we describe the available evidence on the efficacy of fertility preservation techniques in young g BRCA1/2 PVs carriers and the safety data on having a pregnancy after breast cancer treatment.
Keyphrases
- breast cancer risk
- end stage renal disease
- systematic review
- middle aged
- chronic kidney disease
- preterm birth
- ejection fraction
- stem cells
- dna repair
- newly diagnosed
- human health
- gene expression
- risk assessment
- electronic health record
- peritoneal dialysis
- prognostic factors
- pregnancy outcomes
- climate change
- big data
- data analysis